Skip to main content

Table 1 Clinical profiles, muscle pathology and PNPLA2 mutations from 45 neutral lipid storage disease with myopathy (NLSDM) patients

From: Neutral lipid storage disease with myopathy in China: a large multicentric cohort study

No.

(Family)

S/A/D

Initial symptoms

Weakness Distribution

Severe limbsa

Subtype

JA

Muscle pathology

PNPLA2 mutations

Parental derivation

Domain

P1 (F1)

M/4/1

HyperCK

NA

NA

AH

+

Lipid

c.659_667del, p.Y220_L222del

P/M

 

P2(F2)

F/4/22

EI

P

B/LL

S/C

+

Lipid

c.353 T > C p.L118P

M

PA

        

c.356C > A, p.T119 N

P

PA

p3(F3)

F/46/3

B/LL

P

R/UL

S

+

Lipid/RVs

c.478_479 insCTCC, p.Q160Pfsa19

NA/NA

 

P4(F4)

F/48/4

B/UL, LL

P

B/LL

S/C

+

Lipid/RVs

c.245G > A, p.G82D

M

PA

        

c.564G > A, p.S188=

NA

 

P5(F5)

F/29/6

Palpitation

NA

NA

C

+

Lipid

c.333_334del, p.S111Rfsa66

NA/NA

 

P6(F6)

M/23/19

Palpitation

NA

NA

C

NA

Lipid

c.918del, p.A307Pfsa13

P/M

 

P7(F7)

M/21/1

Chest pain

NA

NA

C

+

Lipid

c.757 + 1G > T

P/NA

 

P8 (F8)

F/41/5

B/UL

P

B/UL

S

+

Lipid/RVs

c.245G > A, p.G82D

P/M

PA

P9 (F8)

M/33/5

Palpitation

NA

NA

C

+

Lipid

c.245G > A, p.G82D

P/M

PA

P10 (F9)

F/35/5

B/UL, LL

P

B/UL

S

+

Lipid/RVs

c.187 + 1G > A

P/M

 

P11 (F9)

M/35/20

Hearing loss

D

B/LL

S/C

+

Lipid/RVs

c.187 + 1G > A

P/M

 

P12(F10)

M/31/13

R/LL

P

R/UL

S/C

NA

Lipid

c.187 + 1G > A

P/M

 

P13(F10)

M/27/15

R/UL

P

R/UL

S/C

+

Lipid/RVs

c.187 + 1G > A

P/M

 

P14(F11)

M/41/3

R/UL, LL

P

R/UL

S/C

+

Lipid/RVs

c.757 + 2 T > C

NA

 
        

c.749A > C, p.Q250P

NA

 

P15(F12)

F/45/3

R/UL

D

R/UL

S

+

Lipid/RVs

c.757 + 1G > T

NA/NA

 

P16(F13)

M/38/1

R/UL

P

R/UL

S

+

Lipid

c.467del, p.P156Lfsa100

NA/NA

 

P17(F14)

M/22/6

R/LL

D

B/LL

S

+

Lipid/RVs

c.434G > A, p.S145 N

NA/NA

PA

P18(F15)

F/42/7

R/UL

P

R/UL

S/C

+

Lipid/RVs

c.6_7insT, p.P3Sfsa62

NA/NA

 

P19(F16)

M/34/1

R/UL, LL

P

B/UL

S/C

+

Lipid

c.475_476 insCTCC, L159Pfsa20

NA/NA

 

P20(F17)

M/35/6

R/UL, LL

P

R/UL

S

+

Lipid/RVs

c.467del, p.P156Lfsa100

NA/NA

 

P21(F18)

M/36/6

B/UL, LL

P

R/UL

S

+

Lipid/RVs

c.697-1G > A

NA/NA

 

P22(F19)

M/3.5/0.17

HyperCK

NA

NA

AH

+

Lipid

c.516C > G p.N172K

M

PA

        

c.918del, p.A307Pfsa13

P

 

P23(F20)

F/34/7

R/UL, LL

P

R/UL

S/C

+

NA

c.291_292insT, p.L98Pfsa8

NA/NA

 

P24(F21)

F/26/2

B/UL, LL

P

B/UL

S/C

NA

Lipid

c.757 + 1G > T

NA/NA

 

P25(F22)

F/17/17

B/UL

P

B/UL

S/C

NA

Lipid

c.798delC, p.A267P fsa53

NA/NA

 

P26(F23)

M/22/5

B/LL

P

R/UL

S/C

NA

Lipid

c.475_476 insCTCC, p.L159Pfsa20

NA/NA

 

P27(F24)

F/30/11

B/LL

P

R/UL

S/C

NA

Lipid

c.757 + 1G > T

NA/NA

 

P28(F25)

F/36/6

B/LL

P

R/UL

S/C

NA

Lipid

c.245G > A, p.G82D

NA/NA

PA

P29(F26)

F/40/10

B/UL

P

B/UL

S/C

+

Lipid

c.245G > A p.G82D

NA/NA

PA

        

c.516 del p.L173C fsa83

NA/NA

 

P30(F27)

F/40/13

R/UL

P

R/UL

S/C

+

Lipid/RVs

c.245G > A, p.G82D

NA/NA

PA

P31(F28)

F/32/9

B/UL

P

R/UL

S

+

Lipid/RVs

c.187 + 1G > A

P/M

 

P32(F29)

F/29/4

R/UL

P

R/UL

S

+

Lipid/RVs

c.757 + 1G > T

P/M

 

P33(F30)

M/37/3

R/UL

P

R/UL

S

NA

Lipid/RVs

c.757 + 2 T > C

P

 
        

c.749A > C, p.Q250P

M

 

P34(F31)

F/42/9

R/UL

P

R/UL

S

+

Lipid/RVs

c.245G > A, p.G82D

P

PA/

        

c.922 del, p.L308Cfsa12

M

 

P35(F32)

F/41/3

R/UL

P

B/UL

S/C

NA

Lipid

c.187 + 1G > A

P/M

 

P36(F32)

F/40/5

R/UL

D

B/LL

S

NA

Lipid/RVs

c.187 + 1G > A

P/M

 

P37(F33)

F/26/9

R/UL

P

R/UL

S

NA

Lipid

c.757 + 1G>T

NA/NA

 

P38(F34)

F/44/7

B/UL,LL

P

B/UL

S/C

NA

Lipid

c.757 + 1G > T

NA/NA

 

p39(F35)

F/30/3

R/UL

P

R/UL

S/C

+

Lipid

c.757 + 1G>T

P/M

 

p40(F36)

F/30/2

R/LL

P

R/UL

S

+

Lipid/RVs

c.750_757del, p.R251Pfsa53

NA/NA

 

P41(F37)

M/17/7

B/LL

P

R/UL

S

+

NA

c.757 + 1G > T

P/M

 

P42(F37)

M/21/1

EI

D

B/LL

S

+

NA

c.757 + 1G > T

P/M

 

P43(F38)

F/40/10

R/UL

D

R/UL

S/C

NA

Lipid/RVs

c.757 + 1G > T

NA/NA

 

P44(F39)

F/27/6

R/UL

P

R/UL

S

NA

Lipid

c.757 + 1G > T

NA/NA

 

P45(F40)

F/30/8

R/UL

P

R/UL

S/C

+

Lipid/RVs

c.757 + 1G > T

NA/NA

 
  1. Abbreviations: S/A/D Sex/onset Age (years)/Duration (years); JA Jordan’s anomaly; R right; B Both; UL upper limb weakness; LL lower limb weakness, EI Exercise intolerance; P proximal; D distal; NA not applicable; S skeletal myopathy; C cardiomyopathy; S/C skeletal myopathy with cardiomyopathy; AH asymptomatic hyperCKemia; RVs rimmed vacuoles; P Paternal; M, Maternal; PA patatin domain
  2. aSevere limbs refer to the most severely involved limbs in physical examination.